Information from the FAMHP :
- 06.08.2020 - Coronavirus: Evaluation of the use of saliva samples as an alternative to sampling via a deep nasal swab to detect SARS-CoV-2, the virus that causes COVID-19
- 30.07.2020 - Coronavirus: Derogation for COVID-19 clinical trials of medicinal products containing or consisting of genetically modified organisms
- 27.06.2020 - Coronavirus and the fight led by the FAMHP: the FAMHP is preparing for a potential pandemic resurgence
- 26.06.2020 - Coronavirus: further extension of the measures taken by the FAMHP to avoid medicinal product shortages
- 26.06.2020 - Coronavirus and the fight led by the FAMHP: the FAMHP carries out hundreds of controls and inspections to ensure the compliance and safety of medicines and health products
- 25.06.2020 - Coronavirus and the fight led by the FAMHP: the FAMHP constantly monitors the safety of treatments
- 24.06.2020 - Coronavirus and the fight led by the FAMHP: solutions implemented by the FAMHP in the face of medical equipment shortages
- 24.06.2020 - Coronavirus: FAMHP adds dexamethasone to the list of medicinal products subject to controlled distribution measures
Directives for medical devices during the COVID-19 pandemic
General information on www.info-coronavirus.be
Information for healthcare professionals via Sciensano
News
Because of the benefits to both patients and healthcare professionals, a study on the use of saliva samples as an alternative to sampling via a deep nasal swab (nasopharyngeal) to detect SARS-CoV-2 using molecular detection tests (PCR) was launched on 28 May 2020.
Study
In the context of the COVID-19 crisis, the European Union adopted a regulation providing for a temporary derogation from European legislation on genetically modified organisms.
On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. Following new information from scientific research, the FAMHP has added dexamethasone-based medicines and raw materials to the list of medicinal products subject to emergency measures.
On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. These measures have now been extended by one month.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly and have devoted a lot of resources to monitoring medical devices delivered to Belgium and imported medicinal products.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly and have devoted a lot of resources to support healthcare professionals and to ensure the quality and safety of medicinal products and medical devices used to treat COVID-19 patients. But the efforts do not stop. The FAMHP is now doing everything to prevent any shortage of medicinal products or medical devices in the event of a second wave of COVID-19.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals facing difficulties with supplies of medicinal products used in the treatment of COVID-19 patients. In addition, given the specific context of use of these medicinal products, the FAMHP has ensured close monitoring of adverse reactions.
Dosing devices for liquid medicines are generally not interchangeable. To avoid dosing errors, the FAMHP recalls the importance of using the dosing device supplied with the medicine.